Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children (Q24197915)

2

Jason W

Nickerson

1 reference

20 October 2023

Maria Ximena Rojas-Reyes

3

Maria Ximena

Rojas-Reyes

1 reference

20 October 2023

Juan David Rueda

4

Juan David

Rueda

1 reference

20 October 2023

Vesna Bacic Vrca

5

Vesna

Cochrane Database of Systematic Reviews

Bacic Vrca

1 reference

20 October 2023

language of work or name

1 reference

30 April 2013

0 references

published in

0 references

cites work

Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Health economics and RSV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Cost effectiveness of palivizumab for RSV prevention in high-risk children in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Cost effectiveness of palivizumab in children with congenital heart disease in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Cost effectiveness of palivizumab in Spain: an analysis using observational data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Passive immunisation against respiratory syncytial virus: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Cost-effectiveness of palivizumab in New Zealand.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Economic analysis of palivizumab in infants with congenital heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Comparison of the cost of hospitalization for respiratory syncytial virus disease versus palivizumab prophylaxis in Canadian Inuit infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Respiratory syncytial virus prophylaxis: cost-effective analysis in Argentina

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Prevalence of respiratory syncytial virus (RSV) risk factors and cost implications of immunoprophylaxis to infants 32 to 35 weeks gestation for health plans in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Net cost of palivizumab for respiratory syncytial virus prophylaxis during the 1998/99 season in northern Alberta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Readmission with respiratory syncytial virus (RSV) infection among graduates from a neonatal intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Respiratory syncytial virus infections in congenital heart defects--hospitalizations and costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Outcome of respiratory syncytial virus infection and a cost-benefit analysis of prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

The potential impact of prophylaxis against bronchiolitis due to the respiratory syncytial virus in children with congenital cardiac malformations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Respiratory syncytial virus prophylaxis in a high-risk population in Argentina: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Impact and cost-effectiveness of respiratory syncytial virus prophylaxis for Kansas medicaid's high-risk children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Prophylaxis against respiratory syncytial virus (RSV), varicella, and pneumococcal infections: economic-based decision-making

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Reliability of medicaid claims versus medical record data: in a cost analysis of palivizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Chronological and clinical characteristics of apnea associated with respiratory syncytial virus infection: a retrospective case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Grading quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Mortality in children from influenza and respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Developing efficient search strategies to identify reports of adverse effects in MEDLINE and EMBASE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

The burden of respiratory syncytial virus infection in young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Cost-effectiveness analysis in the courts: recent trends and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Substantial variability in community respiratory syncytial virus season timing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Driscoll Children's Hospital respiratory syncytial virus database: risk factors, treatment and hospital course in 3308 infants and young children, 1991 to 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Incidence of apnea in infants hospitalized with respiratory syncytial virus bronchiolitis: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Mortality associated with influenza and respiratory syncytial virus in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Immunoglobulin for preventing respiratory syncytial virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Changing costs and the impact on RSV prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

7 January 2021

Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

7 January 2021

[Methodological aspects of economic evaluation in pediatrics: illustration by RSV infection prophylaxis in the French setting]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

7 January 2021

Economic evaluation of palivizumab in children with congenital heart disease: a Canadian perspective

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

7 January 2021

Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

7 January 2021

PRS17 COST-EFFECTIVENESS OF RESPIRATORY SYNCYTIAL VIRUS PROPHYLAXIS WITH PALIVIZUMAB FROM THE PERSPECTIVE OF A SOUTHERN US MEDICAID AGENCY

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

7 January 2021

How well do search filters perform in identifying economic evaluations in MEDLINE and EMBASE

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

7 January 2021

Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

7 January 2021

Cost of hospitalization for respiratory syncytial virus chest infection and implications for passive immunization strategies in a developing nation.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

7 January 2021

Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

7 January 2021

Cost–effectiveness of palivizumab in infancy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

7 January 2021

Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006602.PUB4

7 January 2021